Clinical Trials Browser

Phase 2/3 × Completed × ibrutinib × Clear all

NCT02801578 2020-02-27

A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)

Phase 2/3 Completed

11 enrolled 7 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell